Table 2.

IPTp-DP delivery effectiveness among pregnant women with exit interviews, modified intention-to-treat population

	Pregnant women with exit interviews (N=1366)
Full delivery effectiveness (with DOT)∗	402 (29%)
Three DP tablets via DOT plus six DP tablets to take home	371 (27%)
Three DP tablets via DOT plus follow-up contacts on days 2–3 to deliver a further six DP tablets	31 (2%)
Partial delivery effectiveness (without DOT)†	154 (11%)
Nine DP tables to take home	151 (11%)
Three DP tablets to take home plus follow-up contacts on days 2–3 to deliver a further 6 DP tablets	3 (<1%)
Non-effective delivery‡	810 (59%)
With DOT and inadequate doses to take home	1 (<1%)
Without DOT and inadequate or no doses to take home	234 (17%)
Health workers did not offer IPTp	534 (39%)
Administer IPTp-DP to pregnant women who are not yet eligible due to timing that does not comply with the guidelines	41 (3%)

Data are n (%). Effective delivery was calculated as the proportion of women attending ANC treated appropriately according to the implementation of IPTp-DP guidelines; an appropriate dose of IPTp-DP is defined as the correct dose of three tablets per day for three days (ie, a total of nine tablets). ANC=antenatal care. DOT=directly observed therapy. DP=dihydroartemisinin–piperaquine. IPTp=intermittent preventive treatment. IPTp-DP=IPTp with DP.

^∗Full effective delivery is defined as the administration of three tablets under DOT for the first dose, followed by six tablets for subsequent doses.

^†Partial effective delivery is defined as the receipt of all nine tablets without DOT.

^‡Any other scenario is classified as non-effective delivery.